Targeted delivery of curcuminoids to treat Alzheimer's disease
Official title: Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD
Funded at 3p Biotechnologies, INC. · NIH-10820082 · Data updated 2026-11-12
This study is testing a new way to deliver natural compounds that may help treat Alzheimer's disease by using tiny carriers to send them directly to the brain, with the hope of reducing inflammation and improving symptoms for people living with the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 3p Biotechnologies, INC. NIH-funded |
| Lab location | 1 site (Prospect, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $499,964 |
| NIH project number | 1R41AG085737-01 |
| Project ID | NIH-10820082 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other types of dementia or neurological disorders unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research aims to develop a new method for delivering curcuminoids, which are natural compounds with potential therapeutic effects, directly to the brain to treat Alzheimer's disease. The approach involves using exosomes, which are tiny vesicles that can cross the blood-brain barrier, to transport these compounds effectively. By applying a novel trans-spinal delivery method, the researchers hope to enhance the targeting of these compounds to areas of the brain affected by Alzheimer's, potentially reducing inflammation and improving symptoms. The study will explore the combined effects of curcumin and bisdemethoxycurcumin on neuroinflammation and related biomarkers.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease by improving drug delivery to the brain.
How similar studies have gone: While the use of exosomes for drug delivery is a promising area of research, this specific approach targeting Alzheimer's disease is relatively novel and has not been extensively tested.
Where this research is happening
-
3p Biotechnologies, INC.
Prospect, United States Active
Researchers
- Principal investigator: Gupta, Ramesh C — 3p Biotechnologies, INC.
- Study coordinator: Gupta, Ramesh C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.